TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03168789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tension Tamer (TT)
Description: Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle education program (SPCTL)
Description: SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
Study: NCT01344512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Description: Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
Study: NCT00451100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
Study: NCT02336178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benefix
Description: Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first.
Study: NCT02950324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
Study: NCT00294554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
Study: NCT03902977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quilting
Description: After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional suture
Description: After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
Study: NCT03053817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
Study: NCT00545454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR150106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR150106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT04248426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATI-2173 Placebo
Description: ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
Study: NCT02484118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis blood flow
Description: The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis blood flow
Description: The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
Study: NCT04057326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oryz-Aspergillus Enzyme and Pancreatin Tablet
Description: 2 tablets/time, 3 times daily,Oral Administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets/time, 3 times daily,Oral Administration.
Study: NCT03918837

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
Study: NCT03586492

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CZT SPECT acquisition
Description: CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment
Study: NCT01815346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Function and Balance Tests
Description: Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Function and Balance Tests
Description: Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
Study: NCT01831388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing techniques
Description: During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Baseline and Transition Dyspnea Indexes
Description: Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
Study: NCT05935124

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WLE first, then B-NBI

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WLE first, then B-NBI
Study: NCT01896167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia
Description: Inhalation of hypoxic air (8-12% oxygen content)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation of atmospheric air
Study: NCT02515370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Friends for Life Circles (FLCs).
Description: The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs
Study: NCT01081652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronised Progesterone
Description: Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
Study: NCT03469037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow with an inspired fraction of oxygen of 100%
Description: Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow with an inspired fraction of oxygen of 100%
Description: Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow with an inspired fraction of oxygen of 21%
Description: Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow with an inspired fraction of oxygen of 21%
Description: Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
Study: NCT02396121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement : Renutryl® Booster
Study: NCT01281124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00744497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study: NCT03109964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation forceps (ETHICON inc.)
Description: Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SURGIFLO hemostatic matrix (ETHICON inc.)
Description: Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
Study: NCT04017728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Percutaneous Vertebroplasty
Description: The cement is injected into the bone metastases directly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Vertebroplasty with Rotary Cutter
Description: The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
Study: NCT05390983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with stent removal
Description: Standard carotid endarterectomy will be extended with the stent removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy with stent removal
Description: Standard carotid endarterectomy will be extended with the stent removal
Study: NCT03019185

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Capsule containing an inert placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Description: Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bardoxolone Methyl
Description: Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
Study: NCT02791373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Mobilisation Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Mobilisation Chemotherapy
Study: NCT03982615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-Lok abutment
Description: Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard healing abutment
Description: Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
Study: NCT01556893

Intervention type: DEVICE
Group type: OTHER
Intervention: LenSx Laser
Description: The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
Study: NCT00003193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00905138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: single ascending doses, oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: multiple dose, oral solution, 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral solution, 5 days
Study: NCT03314597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise
Description: Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile platform exercise
Description: Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
Study: NCT02422056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of saline in the same rate used for the intervention group
Study: NCT02158520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01653184

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
Study: NCT02719678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General health checks
Description: The intervention group is invited to up to three general health checks over a 10-year period
Study: NCT01659619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: 125mg in normal saline single use infusion for 5 min.
Study: NCT03497754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probefix
Description: A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
Study: NCT00969878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-CD Vaccination
Description: On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.